Vor Ort
Merkzettel Warenkorb
Produktbild: New Targets in Inflammation

New Targets in Inflammation Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, supported by an educational grant from Boehringer Ingelheim

97,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

16.10.2012

Herausgeber

N. Bazan + weitere

Verlag

Springer Netherland

Seitenzahl

147

Maße (L/B/H)

23,5/15,5/1 cm

Auflage

1996

Sprache

Englisch

ISBN

978-94-010-6265-7

Beschreibung

Portrait

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.

Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

16.10.2012

Herausgeber

Verlag

Springer Netherland

Seitenzahl

147

Maße (L/B/H)

23,5/15,5/1 cm

Auflage

1996

Sprache

Englisch

ISBN

978-94-010-6265-7

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: New Targets in Inflammation
  • Preface. 1. The History of Anti-Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2synthase-1 (COX-1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase-2; S.H. Ferreira. 5. Brain COX-2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase-2 Inhibitors; A.W. Ford-Hutchinson. 7. Characteristics of Cyclooxygenase-1 and Cyclooxygenase-2-Deficient Mice; S.G. Morham, R. Langenbach. 8. X-Ray Crystal Structure of Human Cyclooxygenase-2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non-Steroid Anti-Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase-2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX-1/COX-2 Inhibition by Non-Steroid Anti-Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX-2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase-2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.